B
Bull
Bull · 25%ICAD
$4.15
Precio del escenario
$3.870
+0.145 (+3.75%)Al cierre
Loading chart…
- High
- 3.880
- Open
- 3.740
- VWAP
- 3.82
- Vol
- 190.13K
- Mkt Cap
- 34.50M
- Low
- 3.710
- Amount
- 726.29K
- EV/EBITDA, TTM
- -9.66
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.
Analyst Ratings (2)
-16.02% downside
Buy
2 Buy
0 Hold
0 Sell
Current: 3.87
Mínimo
3.00
Promedio
3.25
Máximo
3.50
Kepler Cheuvreux
Reduce
—
2026-01-08
Kepler Cheuvreux
2026-01-08
Precio objetivo
—
Reduce
Laidlaw & Co.
Hold
—
2025-04-17
Laidlaw & Co.
2025-04-17
Precio objetivo
—
Hold
Lake Street
Strong Buy
$5
2023-07-19
Lake Street
2023-07-19
Precio objetivo
$5
Strong Buy
JMP Securities
Buy
$4
2023-04-13
JMP Securities
2023-04-13
Precio objetivo
$4
Buy
Oppenheimer
Buy
$4
2023-04-04
Oppenheimer
2023-04-04
Precio objetivo
$4
Buy
Métricas de valoración
The current forward P/E ratio for ICAD Inc (ICAD) is -9.50, compared to its 5-year average forward P/E of -9.83.
Alphio AI Price Scenarios for ICAD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
7.006-15GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
7.006-15GlobenewswireHAPPY FATHER’S DAY and $HARHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger: SVT, SSBK, LNSR, iCAD
7.006-09GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SVT, LNSR, ICAD, SSBK on Behalf of Shareholders
7.006-09PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, LNSR, ICAD on Behalf of Shareholders
7.006-09Globenewswire$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of SVT, SSBK, LNSR, iCAD to Act
ICAD FAQ — answered by Alphio AI
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
2 analysts cover ICAD: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 3.25.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.